Teck Resources Ltd. Cl B Stock Falls Monday, Underperforms Market
Dow Jones2026/10/05 20:35This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Teck Resources Ltd. Cl B TECK.B slid 0.98% to C$96.80 Monday, in what proved to be an otherwise all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.04% to 35,518.55. Teck Resources Ltd. Cl B closed 3.1% short of its 52-week high of C$99.91, which the company achieved on September 8th. Trading volume of 1.1 M shares remained below its 50-day average volume of 1.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled October 5, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 05, 2026 16:35 ET (20:35 GMT)
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Teck Resources Ltd. Cl B TECK.B slid 0.98% to C$96.80 Monday, in what proved to be an otherwise all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.04% to 35,518.55.
Teck Resources Ltd. Cl B closed 3.1% short of its 52-week high of C$99.91, which the company achieved on September 8th.
Trading volume of 1.1 M shares remained below its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled October 5, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 05, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
